ClinicalTrials.gg
CompletedNCT05069779Updated Oct 6, 2021

Diazepam and Blood Pressure Regulation

An Early Phase 1 interventional study of Diazepam in Healthy, sponsored by University of Brasilia. Completed at 1 site in Brazil. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-06.

Sponsored by University of Brasilia · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.
  • Registered 4 years 1 month after the study started (first participant enrolled Aug 2017, registered Sep 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The aim of this study is to determine the acute effects of diazepam on beat-to-beat blood pressure variability and baroreflex control.

Read the detailed description

Benzodiazepines are widely prescribed for a variety of clinical conditions. However, its cardiovascular consequences remain controversial. In this study, the investigators sought to determine the acute effects of a single dose of oral diazepam (10mg) on resting beat-to-beat blood pressure variability and cardiac and sympathetic baroreflex sensitivity in a cohort of young, healthy individuals.

02

Conditions studied

  • Healthy

Keywords

  • Blood pressure
  • Benzodiazepine
  • Autonomic nervous system
03

In context

Lead sponsor

University of Brasilia is the lead sponsor of 68 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 40 years of age
  • Healthy, free of known cardiovascular, metabolic, or musculoskeletal disease

Exclusion criteria

Exclusion Criteria:

  • History of smoking (tobacco or cannabis), defined as any smoking within the past 3 months
  • Diagnosed cardiovascular or metabolic disease(s)
  • Prescription of chronic medications other than oral
  • History of hypertension or presence of arrhythmia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Diazepam

    Oral

    Drug: Diazepam

  • Placebo comparator
    Placebo

    Oral

    Drug: Diazepam

Interventions

  • Oral administration of 10 mg of diazepam

06

What researchers measure

Primary outcomes

  1. Resting beat-to-beat blood pressure variability

    Finger photoplethysmography

    Time frame: Change from baseline at 60 min

  2. Systolic and diastolic blood pressure

    Oscillometric device

    Time frame: Change from baseline at 60 min

Secondary outcomes

  1. Muscle sympathetic nerve activity

    Microneurography

    Time frame: Change from baseline at 60 min

  2. Baroreflex sensitivity

    The relationship between changes in beat-to-beat blood pressure and heart rate (cardiac baroreflex) or MSNA (sympathetic baroreflex).

    Time frame: Change from baseline at 60 min

07

Study locations

1 site
  • University of Brasilia
    Brasília, DF 70910-900, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — The data underlying this project will be shared on reasonable request to the principal investigator.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in May 2019, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Oct 6, 2021
StartActual
Aug 1, 2017
Primary completionActual
May 20, 2019
CompletionActual
May 20, 2019
Last update
Oct 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05069779
Lead sponsor
University of Brasilia
Responsible party
Sponsor
First posted
Oct 6, 2021
Start date
Aug 1, 2017
Primary completion
May 20, 2019
Completion
May 20, 2019
Last update
Oct 6, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion